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Objective. To examine our experience with cytology and histology biopsy of the liver and to define methods for improvement of
diagnosis of primary liver tumors. Methods. This include retrospective study of 189 biopsies of 185 liver masses for cytological or
histological analysis. Patients were subdivided into two groups. Group 1 consisted of 124 suspected metastasis. Group 2 consisted of
61 suspected primary neoplasms. Biopsies were considered positive or equivocal. In equivocal cases, special stains were performed.
In Group 2, cases were classified by contrast CT or MRI as to (I) classic HCC, (II) infiltrated HCC, or (Ill) equivocal. Results.
Definitive diagnosis was obtained in 117/124masses (94%) in Group 1, 48/61 masses (79%) in Group 2, and (Ill) equivocal 13 cases in
Group II. In two equivocal cases in which special stains were performed, they were reclassified as HCC. In 8/13 cases, CT findings
were consistent with HCC. Conclusion. Liver biopsies are useful in obtaining a definitive diagnosis of suspected metastatic liver
disease. Biopsy results are less reliable in patients with suspected primary liver tumors. In these situations, strategies can include
basing treatment on imaging criteria or use of newer special pathological stains. Advances in Knowledge. Use of newer special
immunological stains improves accuracy in definitive diagnosis of primary liver tumors.
1. Introduction
Percutaneous fine needle aspiration cytology (FNAC) and
automated needle core biopsy (NCB) for histological retrieval
have been used to diagnose malignancy in abdominal organs
for over three decades [1, 2]. These techniques of FNAC and
NCB have been useful in obtaining a diagnosis of focal liver
masses [3–5]. In the past when previously performing liver
biopsies of focalmasses the biopsies oftenwere performed for
metastatic disease. However, more recently we have noticed
an increasing number of biopsies for suspected hepatocellular
carcinoma. The epidemiology of hepatocellular carcinoma
(HCC) is changing in North America and Europe for sev-
eral reasons, including the viral hepatitis epidemic and the
increasing number of patients diagnosed with nonalcoholic
fatty liver disease [6]. In these groups, surveillance is difficult
and has included use of serum markers such as alpha feto
protein (AFP) and imaging with ultrasound, CT, or MRI.
However, definitive diagnosis often requires biopsy of focal
masses. We have felt that we had maintained very high
rate of specific diagnosis for fine needle aspiration cytology
(FNAC) or needle core biopsy (NCB) for focal livermasses for
possible metastatic disease but have noticed more equivocal
results for FNAC or NCB for patients with suspected primary
liver tumors. The image guided biopsy strategies are only
effective in achieving the goal of reducing mortality if HCC
can be adequately distinguished from regenerating nodules
by cytology or histology. Our general impression is that
definitive diagnosis ofHCC is not as easilymade asmetastatic
carcinoma.Therefore, the purpose of this paper is to examine
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our experience with cytology and histology to find key
aspects for the improvement of diagnosis of primary liver
tumors, that may be helpful for physicians that encounter
patients with suspected primary liver tumors.
2. Materials and Methods
This is a retrospective study conducted at our institution
between July 8, 2005 and December 17, 2009. This has full
Institution Review Board approval at our institution. Written
informed consent was waived. This data set consisted of 240
consecutive targeted liver biopsies performed at our institu-
tion. To qualify for the study, a patient had to be over age
18 years and must have a contrast enhanced cross-sectional
imaging, magnetic resonance imaging (MRI), or computed
tomography (CT) for evaluation of a suspected liver tumor.
Computed Tomography was performed with either a Gen-
eral Electric (16 Detector) high speed (General Electric,
Milwaukee, WI) or a Siemens Somotom Definition Dual
Source (64 Detector) CT (Siemens Medical Solutions USA,
Malvern, PA). This included a 4 phase CT including base,
arterial phase (approximately 40 seconds), portal venous
phase (approximately 90 seconds), and delayed images (3 to 5
minutes) after injection of contrast. Contrast wasOmnipaque
350 (GE Healthcare, Princeton, NJ) injected at rate of 3 to
5mL/second for a total of 125mL using a power injector.
Images were acquired on a 1.5 Tesla General Electric Signa
MRI Scanner system (GEMedical Systems, Milwaukee, WI),
equipped with a phased array torso coil for signal reception.
The imaging protocol was as follows: coronal single shot fast
spin echo (SSFSE) transverse SSFSE, transverse noncontrast,
T1-weighted, 2D spoiled gradient echo sequence in-phase
and out-of-phase, 3D fast relaxation fast spin echo coronal
T2-weighted MRCP, 2D thick slab T2-weighted MRCP, and
transverse precontrast T1-weighted 3D spoiled gradient echo
pulse (LAVA) sequence. Then, usually 20mL of Omniscan
(GE Medical Systems, Milwaukee, WI) was injected intra-
venously at 2 cc/sec and transverse LAVA sequences were
obtained with the same parameters as above during the
arterial, portal venous, and equilibrium phases. Patients
referred to our institution for biopsy with outside imaging
were included in the study if their images were stored,
deemed adequate, and available on our Picture Archiving and
Communications (PAC) system. (I-Site, Koninklijke Philips
Electronics, N.V., Foster City, CA).
Twenty-nine patients were excluded from our study
since their imaging studies were not available on our PACs
system. Fifteen additional patients were excluded as needle
aspiration yielded a fluid collection or potential abscess. Since
this study addressed percutaneous fine needle aspiration
cytology (FNAC) biopsies of liver masses only, six patients
whose biopsieswere performedunder endoscopic ultrasound
guidance and one percutaneous biopsy of a bile duct were
excluded. 189 liver biopsies which included either FNAC for
cytological diagnosis or needle core biopsy (NCB) of the liver
for histological diagnosis and or both were obtained. In two
cases the masses were rebiopsied and in one case, the mass
was biopsied three times, and thus 185 masses were included
as the data set in this study. All fine needle aspirations were
performed in a similar of fashion using a 22-gauge Chiba type
needle with biopsy performed either with an aspiration or
non-aspiration technique. At the discretion of the operator.
The majority of biopsies are performed under ultrasound
guidance with needle visualization documentation in the
mass.
A cytotechnologist was present in the radiology suite
to collect the FNAC and NCB specimens. Two slides were
prepared from each pass using the “pull-apart method”. One
specimen was air dried and the other was fixed in alcohol and
immediately evaluated for adequacy by the cytotechnologist
following staining with toluidine blue. The air-dried smears
were later stained with a modified Giemsa stain in the
laboratory and the toluidine blue stained slides were re-
strainedwith a Papanicolaou stain; both types of preparations
were evaluated for final diagnosis. The needle from each pass
was rinsed in Saccomanno fixative for cell block preparation
and reviewed in conjunction with the direct smears for
final adequacy determination and final diagnosis. Continued
needle passes were performed until cytological technologist
confirmed adequacy of the specimen. For NCB, touch prep
technique was used in a similar fashion.
Furthermore, liver needle core biopsies (NCB) using an
automated biopsy gun or biopsy device were performed
with a number of different manufacturers automated devices.
Most commonly utilized are automatic 18-gauge core biopsy
needle. All NCBs were performed in a similar fashion using
ultrasound or CT guidance to document needle position
within the lesion. NCBs were collected into formalin, pro-
cessed and sectioned in the usual fashion, and stained with
hematoxylin and eosin. All percutaneous liver biopsies were
performed under conscious sedation usually using midazo-
lam hydrochloride (Versed. Hoffman-La Roche) and fentanyl
citrate. Study patients were subdivided into two groups based
on the clinical and radiologic impression. Group I consisted
of 124 biopsies (FNAC and/or NCB) in 124 masses (from 59
men and 65 women; average age 60.3 years) with a suspected
diagnosis of hepatic metastases.
In Group I, if the final cytology or histology report was
“adenocarcinoma, site unspecified, this was not considered
as a specific diagnosis but was considered as a malignant
diagnosis. Group II consisted of 65 biopsies in 61masses from
61 patients (34 men and 27 women; average age of 58) with
a suspected diagnosis of primary liver tumor. We had 185
masses in our database. For thosewith rebiopsy, only themost
definitive biopsy result was included. Forty-nine of sixty one
(80%) of Group II patients had underlying cirrhosis which
was secondary to hepatitis B or C in 38 patients, alcohol-
related disease in six, NASH in two, and HCV/HIV in two
and autoimmune hepatitis in one. Twelve patients in Group
II had no history of hepatitis or cirrhosis. In both groups, the
cytology and pathology reports were obtained from the elec-
tronic medical record.These results were separated into cases
in which a specific diagnosis of a neoplasm or benign entity
was made. In Group II, there were 10 reports where the final
diagnosis stated, “suspicious for hepatocellular carcinoma.”
These were considered as specific diagnoses.When equivocal
cytology and pathology results were encountered inGroup II,
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Table 1: Results.
FNA CB FNA and CB
Suspected hepatic metastasis
Specific diagnosis 56% (70/124) 68% (34/50) 60% (75/124)
∗Diagnosis malignant versus benign 93% (115/124) 96% (48/50) 94% (117/124)
Suspected primary neoplasms
Specific diagnosis 70.5% (43/61) 67.5% (27/40) 79% (48/61)
Total 85.4% (158/185) 83% (75/90) 89.1% (165/185)
∗Diagnosis of malignancy, but type not specified.
the specific reports and slides were reviewed and classified
as 1 = atypical hepatocyte, 2 = HCC versus METS, 3 = HCC
versus regenerating nodules, 4 = HCC versus adenoma, 5 =
inadequate, 6 = abscess, and 7 =Nomalignancy. If core biopsy
or FNAC was performed on different dates then each report
was listed separately.
Slides from FNAC and NCB cases for patients in Group
II with equivocal diagnoses were rereviewed by a cytopathol-
ogist (LH) with more than 20 years of experience and a
pathologist (JB) with more than 25 years of experience of the
FNAC (LH) and the NCB specimens (JB), respectively. They
reviewed for any possible misinterpretation by the original
pathologist [6]. Furthermore, cell block or core material
was applied if possible for immunohistological stains for
HEPPAR-1 and glypican-3 [7].
The prebiopsy CT or MRI from all available cases in
Group II was re-analyzed by a single radiologist (JPM) with
more than 25 years of experience.They were classified as pat-
tern I (Focal HCC)—an arterially enhanced mass with a well
defined capsule and washout of contrast on delayed imaging
in a patient with chronic hepatitis.This includesmodification
of prior imaging criteria against a background of chronic liver
disease (cirrhosis) [8–10]. This also corresponded to the liver
imaging and reporting data system (LI-RADS) of definitive
HCC [11]. Pattern II consisted of a diffuse irregular enhancing
masswith hypervascular portal vein invasion in a patientwith
hepatitis and chronic liver disease.This corresponded to a LI-
RADs category 5V, definitiveHCC. Pattern IIIwas considered
equivocal for diagnosis based upon lack of pattern I or pattern
II. None of the masses were considered definitely benign.
3. Results
Overall, a definitive diagnosis of malignancy was rendered in
165/185 cases (89.1%) based on findings from FNAC and/or
NCB results and included bothGroup I andGroup II patients
(Table 1). However, when considered separately, Group I
and Group II demonstrated differences in the percentage of
definitive diagnoses. A diagnosis of malignancy or benign
was rendered more frequently in cases where metastatic
disease was suspected (94%) compared to cases where hep-
atocellular carcinoma was suspected (79%). In 117 of 124
(94%) in Group I had a definitive malignant versus benign
diagnosis. Core biopsy also more frequently demonstrated
definitive malignant versus benign diagnosis than FNA in
Group I in 48 of the 50 cases (96%). Furthermore, in the 2 core
biopsies in this group that were equivocal, the FNAC results
were diagnostic. Therefore 50 of 50 (100%) of those masses
with suspected metastatic disease had a definitive malignant
versus benign diagnosis by either FNAC orNCB. In Group II,
48/61 masses (79%) had a definitive malignant versus benign
diagnosis. In Group II, core biopsy improved detection of
primary malignant disease in only 5 additional patients.
CT and MRI were reviewed 54/61 in Group 2 cases and
classified as pattern I, pattern II, or pattern III (seven CTs
were not retrievable). Pattern I of a classic HCC was seen in
27 of 54 (50%) of cases. Pattern II of an infiltrating tumor
and portal vein thrombosis was seen in 8 of 54 (15%) of
cases. Pattern III of an equivocal CTs or MRIs was seen
in 19 of 54 (35%) of cases. In 14 of 19 equivocal CTs or
MRIs cytology/pathology was helpful for giving a definitive
diagnosis.
Furthermore, CT and MRI were analyzed for specific
imaging features of HCC in all of the 13 equivocal cytology
or pathology of primary liver masses. In 8 of these cases,
the radiologic characteristics were nearly pathognomonic for
HCC in the setting of cirrhosis (Figures 1 and 2) (Table 2).
Six of these cases were classified as pattern I (Classic HCC)
with an encapsulated enhancing mass and delayed washout
in a cirrhotic liver. Two masses were classified as pattern II
with an infiltrating mass and portal vein thrombosis in a
cirrhotic liver. 5/13 were equivocal on CT or MRI (Table 2)
(Figures 3 and 4). All classic or probable HCCs identified by
CT were confirmed by follow-up resection, local progression
of disease, or patients expiring with the presumed diagnosis
of HCC, except for one case lost to follow-up. Of the 5
equivocal cases on CT or MRI, 1 expired from HCC, 2 had
progression of disease, one had a wedge resection revealing
HCC and one was an adenoma (Figures 3 and 4). Of the
13 equivocal cytology/histology results, 6 were path proven
after operation. Five of these were HCC and one was a
hepatic adenoma after operating resection. In 5 cases there
was local progression of disease or patients expired, thus with
presumed diagnosis of HCC. One is alive and 1 is lost to
follow-up (Table 2). The encoded report results from FNA
(and core biopsy when performed) of the 13 equivocal cases
are also presented in Table 2.
Of these 13 equivocal cytology or pathology cases, six
had sufficient cell block or core biopsy material to permit
retrospective application of immunohistochemical (IHC)
stains for HEPPAR-1 and glypican-3 (Figure 2). The results
are shown in Table 3. One case was inconclusive, three
were positive only for HEPPAR-1, and two were positive for




Figure 1: Case 5. History: 60 year-old male with cirrhosis due to hepatitis B with AFP of four. Surgically resected HCCs. Initial MRI
demonstrates the following. (a) TI weighted fat suppressed LAVA base scan shows region of decreased signal intensity (arrow). (b) Post
gadolinium enhancedMRI in arterial phase shows encapsulated enhancingmass in the left in the lobe of the liver (arrow). (c) After gadolinium
in portal venous phase, there is a central wash-out with well-defined capsule (arrow). (d) Fine needle aspiration was deemed suspicious for
well differentiated HCC but could not exclude adenoma. The cell block shows groups of hepatocytes forming a thickened trabecular pattern
lined by endothelial cells. The hepatocytes have increased nuclear/cytoplasmic (N : C) ratio and occasional prominent nucleoli. (e) After
resection of the mass the CT shows surgical clips. Pathology revealed well differentiated HCC.
both antibodies. If positive for both immunohistochemical
stains, this is considered to be diagnostic, while if only one
immunostain was positive, this was considered as equivocal
[7].
4. Discussion
Percutaneous fine needle aspiration biopsy of abdominal
masses guided by imaging has been performed for over
30 years [2]. With further developments, percutaneous
automated biopsy needles have been used for histological
retrieval of tissue from abdominal organs [1]. With improved
imaging, refinements in biopsy needles, and newpathological
techniques, there have been a variety of publications attesting
to both high sensitivity and specificity for either fine needle
aspiration biopsy or automated needle biopsy of abdominal
masses. Numerous publications since the mid-1980s have
demonstrated that liver FNAC has sensitivities greater than
85% and a specificity as high as 100%, with the highest
sensitivity when FNAC is combined with core biopsy [3–5].
As our study demonstrates, FNAC and core biopsy have
different limitations prompting equivocal diagnoses. Our
findings and other reports have demonstrated that defini-
tive diagnoses are less frequent in cases of hepatocellular
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Figure 2: Case 11. History: 61 year-old-male with AFP of 149 with alcoholic cirrhosis and HCC after transplant. (a) Arterial phase MRI,
postgadolinium LAVA sequence showing arterial enhancing lesion (arrow). (b) Post gadoliniumMRI during the portal venous phase showed
central washout with well defined capsule (arrow). (c) Fine needle aspiration and core were obtained. Fine needle aspiration was suspicious
for well differentiated HCC but could not exclude adenoma. Deeper sections of the cell block material revealed acinar-like and branched
trabecular patterns of hepatocytes as well as an altered reticulin pattern (not shown). Based on the deeper sections and the positive IHC stain
results for glypican-3 (shown here) and Hep Par 1 (not shown), the biopsy is consistent with hepatocellular carcinoma, well-differentiated.
Patient had RFA and then liver transplant which revealed HCC.
carcinoma than metastasis disease. This is true for other
primary malignancies, including the thyroid [12, 13]. Reports
by both Bru et al. and Matsushiro et al. found that FNAC
diagnosis of hepatocellular carcinoma was definitive in only
62% and 61.5% respectively, even when combined with core
biopsy [14, 15]. However, others have shown that combining
core biopsy with FNAC can improve diagnostic accuracy.
Matsushiro et al. demonstrated that adding histological exam
via core biopsy improved the positive diagnosis rate to 87%
of cases while cytology alone had a positivity rate of 61.5% for
the diagnosis ofHCC [15]. In our series, we had an overall rate
of establishing a diagnosis of 89.1%. (79% for HCC and 94%
for suspectedmetastatic disease, Table 1). Sowhy is there such
a discrepancy in establishing a diagnosis ofHCC and how can
diagnosis accuracy be improved?
Hepatocellular carcinoma is particularly challenging for
both FNA and CB diagnosis. To better understand the chal-
lenge, we must understand that all HCCs are not the same.
HCC is graded based from I to IV to reflect tumor dif-
ferentiation and the presence of one or more clonelike cell
population [16, 17]. Grade I HCCs can be difficult to distin-
guish from benign regenerative nodules and adenomas since
both show minimal nuclear pleomorphism and prominent
nucleoli and have abundant granular cytoplasm reflecting
liver differentiation. Architectural features can be the best
clues to the diagnosis and include a trabecular pattern and
prominent vascular pattern which can be visible on both
cytologic smear and core biopsies [18, 19]. This creates a
problem for diagnosis. Grade IV HCCs are very poorly
differentiated and may be difficult to distinguish from high-
grade tumor of non-hepatocellular origin, since features of
liver differentiation may not be present [16]. In our series,
the ability to distinguish grade I HCC from regenerating
nodule or adenomas was themost common reason for lack of
definitive diagnosis of HCC by both cytology and histology.
Hepatic adenomawas included in the differential diagnosis of





Figure 3: Case 8. History: 72 year-old-male with cirrhosis due to alcoholism with AFP of five. Patient had surgical wedge resection with
findings consistent with HCC. (a) Initial arterial CT phase shows encapsulated mass with minimal enhancement (arrow). (b) Portal phase
shows well-demarcated area of decrease density with peripheral rim (arrow). (c) Delay imaging demonstrating some washout in this lesion
(arrow).This was judged as equivocal forHCCon review. At this time, five FNA’s and one core sample whichwere thought to be nondiagnostic
of HCC and were thought to be regenerating nodule versus HCC. (d) MRI with Eovist with 30 minutes delay scan demonstrating area
with decrease signal intensity (arrow). (e) An addition a satellite lesion (arrow) was identified cephalad to primary lesion. Three cores were
performed on the larger mass which were nondiagnostic and showed no malignancy. (f) Two year follow-up CT demonstrating mass which
was locally invasive withmultiple satellite lesions throughout the liver (arrows). (g) Other five FNA passes and five cores were obtained at that
time which were considered to be satisfactory but nondiagnostic formalignancy. Less than 10% of the histology sample contained hepatocytes
for evaluation. Somewere disposed in nodules with altered reticulin (not shown).The cells havemoderate N : C ratios and are not particularly
atypical. Surgical wedge resection was performed which revealed HCC.
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Figure 4: Case 7. History: 51 year-old-male with no cirrhosis, AFP 1.8, and no hepatitis. At surgery this was pathologically proven to represent
liver adenoma. (a) Arterial phase CT demonstrating enhancing mass with lobulated margin (arrow). (b) Delay images demonstrating
persisting enhancement (arrow) with focal hypodense area noted centrally. This was considered an equivocal mass on review. (c) Fine needle
aspiration biopsy with three passes and three core biopsies demonstrated epithelial neoplasm and adenoma versus HCC. This was reviewed
at an outside institution with the diagnosis of well-differentiated HCC. The smears are cellular and show hepatocytes with minimal atypia
in sheets and small clusters. Prominent capillaries are noted within the sheets and endothelial cells are noted to be encircling clusters of
hepatocytes. Post-surgery pathology revealed this to be adenoma.
the final cytology/pathology report in five masses after either
FNAC or core biopsy (Table 2). Three of these patients had
cirrhosis. In the other patients with cirrhosis, regenerating
nodule versus HCC was mentioned in the final cytology or
histology report (Table 2). This diagnostic dilemma may be
occurring more frequently due to surveillance programs in
patients with underlying liver disease. Not only do these
patients have a background of disease with cellular fea-
tures that can easily mimic malignancy such as balloon
degeneration, inflammatory, infiltrate and apoptosis, but the
hepatocellular carcinomas targeted for detection are more
likely to be welldifferentiated, thus being particularly difficult
to distinguish from the background diseased liver.
How can the problem of distinguishing a grade I HCC
from a benign process be addressed? A number of immuno-
histochemical (IHC)markers have been put forward as possi-
bly helpful in establishing the diagnosis of focal liver lesions.
These stains are not be well known to the radiology commu-
nity, but if requested, they may be useful in establishing or
excluding a diagnosis of hepatocellular carcinoma. Markers
such Hepatocyte Paraffin Antigen-1 (Hep Par 1), Glypican-3,
CD-34, to name a few have been touted as sensitive markers
to help distinguish HCC from non HCC malignancy, and
are helpful to distinguish Grade 1 HCC form benign liver
nodules (Figure 2). Reticulin staining has been traditionally
used to enhance the trabecular architecture of primary liver
lesions. Immunohistochemical staining with CD-34 may
demonstrate diffuse reactivity in HCC and can also be useful
[20–24]. It is important for the physicians to know that there
are IHC markers that may be helpful when they obtain a
biopsy of an equivocal biopsy of potential HCC. Although
the best available markersmay change, they currently include
HepPar-1, glypican-3, andMoc-31, amongothers [25–27].The
European Association for the study of liver disease published
recommendation in 2012 that “immunostaining for GPC3,
HSP70, and glutamine synthetase and/or gene expression
profiles (GPC3, LYVE1, and survivin) is recommended to
differentiate high grade dysplastic nodules from early HCC.
Additional staining can be considered to detect progenitor
cell features (K19 and EpCAM) or assess neovascularization
(CD34)” [28]. Another recent study has shown that the
immunohistochemical panel of Golgi protein 73 (GP73),
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Table 2: Features of the equivocal cases.
Case AFP Cirrhosis CT Diagnosis FNA Core
1 6.6 C I (classic) RFA-alive 1 None
2 49 B + C III equivocal Expired HCC 2 None
3 14.6 C + ETOH III equivocal Progression 1, 1 3
4 241 C I (classic) Path proven HCC-surgery 3 None
5 4.1 B I (classic) Path proven HCC-surgery 4 None
6 3.6 C I (classic) Path proven HCC-surgery 6 2
7 1.8 None III equivocal Adenoma 4 4
8 5 C III equivocal Path proven HCC-surgery 3, 7 7, 7, 7
9 None ETOH II infiltration Died HCC 5 None
10 14,044 C II infiltration Hospice HCC 1, 3 7
11 149 ETOH I (classic) Path proven HCC-surgery. RFA transplant 4 7
12 6.4 None III equivocal Progression 7 4
13 19.5 C I (classic) Lost to follow-up 4 7
1: atypical hepatocyte; 2:HCCversusMETS; 3:HCCversus regenerating nodules; 4:HCCversus adenoma; 5: inadequate; 6: abscess; 7: nomalignancy. Equivocal
cases including Alpha Fetoprotein (AFP) values and presence of cirrhosis including etiology for example hepatitis C (C), hepatitis B (B), or alcohol (ETOH).
The review of CT results, patient follow-up and classification of results from the cytology or histology report.
Table 3: Results of stains applied retrospectively on equivocal
biopsies.
Case CT Diagnosis HepPar1 Glypican3
3 III equivocal Progression pos neg
5 I (classic) Path provenHCC-surgery Inconclusive Inconclusive
8 I (classic) Path provenHCC-surgery pos neg







13 I (classic) Lost tofollow-up pos pos
∗7 of the 13 equivocal cases did not have sufficient material for these stains.
glypican-3 (GPC 3), and CD 34, as well as reticulum stain,
is highly specific in the diagnosis of HCC [29]. However,
any of these staining techniques can be performed only on
core biopsies (or exceptionally abundant cell blocks) and
a sufficiently adequate, representative sample may not be
available. In the 13 equivocal cases in our series, there was
sufficient material to apply IHC markers in only six cases.
Three of those six cases had CT MRI imaging pattern 1
(classic, see Table 3) of which two were positive for both
markers and could, in retrospect, be considered as HCC by
histopathology, using immunohistochemical markers. How-
ever, the other cases were positive for only one marker or
were inconclusive (Table 3). Development of molecular tests
may also eventually prove useful in distinguishing HCC from
reactive disease; however, cost effectiveness will need to be
considered when these are developed and implemented since
molecular testing is currently very expensive.
What other things may be helpful to establish the diagno-
sis of HCC if there is an equivocal cytological or histological
diagnosis? Rebiopsy with a larger core needle may be con-
sidered; low grade HCCs may still be difficult to distinguish
from hepatocellular adenomas, as occurred in three of our
cases where rebiopsy was performed (Figure 3). While there
is poor diagnostic ability of serum AFP to detect HCC
[30], serial increase of AFP value clinically may be helpful
as a complementary method in chronic hepatitis patients
under surveillance for HCC [31].Thus increasing serum AFP
in a cirrhotic patient with a new liver mass with typical
features is helpful. More commonly, correlation with imaging
findings in cirrhotic patients may play a key role, so that
treatment may be undertaken without a definitive diagnosis.
The European Association for the study of the liver has states
“Noninvasive criteria can only be applied to cirrhotic patients
and are based on imaging techniques obtained by 4-phase
multidetector CT scan or dynamic contrast-enhanced MRI.
Diagnosis should be based on the identification of the typical
hallmark of HCC (hypervascular in the arterial phase with
washout in the portal venous or delayed phases). While one
imaging technique is required for nodules beyond 1 cm in
diameter, a more conservative approach with 2 techniques
is recommended in suboptimal settings” [28]. The American
College of Radiology has also proposed a LI-RADS concept of
referring primary liver tumors from LR 1—definitely benign
to LR 5—definitely HCC. Thus LR 4 or LR 5 lesions might
be considered for definitive treatment as HCC, while LR 3
lesions as intermediate probability may require the potential
for biopsy for diagnosis [11]. These are the cases in which
liver biopsy may be useful. In our analysis of 54 CTs or
MRIs, 19 of the CTs were of pattern III with an equivocal
CT diagnosis. Biopsy was definitive of HCC in 14 of 19 of
these cases. However, of these 54 cases, the CT or MRI was
considered to be of a pattern I or a classic appearance of
HCC in 27/54 cases. In 8/54 cases, diffuse tumor with portal
venous invasion was also highly suggestive of HCC. In these
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cases, biopsy could be considered redundant. Of interest in
our equivocal biopsy, group of patients with primary liver
masses, CT and MRI were very suggestive of a diagnosis in
8 of 13 masses while 5 of 13 were equivocal. Therefore, in
the case with equivocal biopsy results, therapy may have to
be based upon the aforementioned CT criteria and tumor
behavior. Thus, eligibility inclusion criteria for diagnosis
and/or treatment could include a positive biopsy with or
without immunohistological stain or typical imaging features
by CT or MRI in the setting of cirrhosis [11, 30, 32–34].
5. Limitations
Weakness of this paper includes the fact that this is a
retrospective study and that multiple different pathologists
were involved in the original interpretation and diagnosis.
In addition, because this is a retrospective study, issues that
may have limited specimen collection are not known, such as
bleeding or technical challenges.
6. Summary
In summary, both percutaneous FNA and NCB demonstrate
the ability to differentiate malignant from benign lesions in
patients with suspected metastatic liver disease. However,
this study confirms that the ability to provide a definitive
diagnosis in HCC using FNAC with NCB or alone is more
challenging. Using FNAC and NCB for suspected primary
liver masses, regenerating nodules, and well-differentiated
HCC frequently has overlapping cytologic features. These
diagnostic challenges and their subsequent management
issues may increase as surveillance of patients with liver
disease becomes more commonplace. These strategies can
include basing treatment onCT orMRIwith specific imaging
features in a cirrhotic liver with the appropriate clinical and
biochemical setting. Effective management may be based
upon not only definitive cytological and histological results,
but also the recognition that there are special immunohisto-
chemical stains that may prove useful in distinguishing HCC
from reactive disease.
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